TPIV 200 is a vaccine that the immuno-oncology company TapImmune is developing as a treatment for platinum-chemotherapy resistant ovarian cancer or triple-negative breast cancer.
TapImmune Announces Enrollment of First Patient in Phase 2 Clinical Trial for Treating Triple-Negative Breast Cancer Funded by U.S. Department of Defense
“We remain grateful to the U.S. Department of Defense and Mayo Clinic for enabling TapImmune to gain invaluable clinical safety and efficacy insight for TPIV200 under this grant,” said TapImmune President and CEO Peter Hoang.
You can now view the presentation from last Thursday’s Virtual Investor Conference call.
TapImmune’s lead candidate, TPIV200, a multiple-epitope anti-folate receptor alpha (FRα) immunotherapy, with an FDA orphan drug designation, has paired up with AstraZeneca’s checkpoint inhibitor Imfinzi in platinum-resistant ovarian cancer patients.
Dr. Kenney will continue to manage the Company’s ongoing and planned clinical programs for its novel, multi-epitope, T-cell vaccine candidates.
TapImmune President and CEO, Peter Hoang, to host live webcast on December 7th at 10:45am.
Tapimmune Inc. President & CEO, Peter Hoang, participates in an interview with The Wall Street Analyzer. Take a listen.
TapImmune President and CEO, Peter Hoang, will be presenting at the 29th Annual Piper Jaffray Healthcare Conference.
Chairman and Strategic Advisor Glynn Wilson, Ph.D., and Senior Director of Molecular Biology & Virology Robert Florkiewicz, Ph.D., will give an oral presentation titled, “Increasing the potency of DNA-based immunotherapies using PolyStart™ peptide expression system,” at the World Vaccine & Immunotherapy Congress West Coast, held Thursday, November 30 – December 1, 2017, at the Loews Coronado Bay Resort in San Diego, CA.
US-based immuno-oncology firm TapImmune has completed patient enrolment in a Phase II clinical trial of its vaccine candidate TPIV200 to treat triple-negative breast cancer (TNBC).